Seviteronel
Androgen biosynthesis inhibitor; Nonsteroidal antiandrogen | |
| ATC code |
|
|---|---|
| Identifiers | |
| |
JSmol) | |
| |
| |
Seviteronel (developmental codes VT-464 and, formerly, INO-464) is an experimental cancer medication which is under development by Viamet Pharmaceuticals and Innocrin Pharmaceuticals for the treatment of prostate cancer and breast cancer.[1] It is a nonsteroidal CYP17A1 inhibitor and works by inhibiting the production of androgens and estrogens in the body.[1] As of July 2017, seviteronel is in phase II clinical trials for both prostate cancer and breast cancer.[1] In January 2016, it was designated fast-track status by the United States Food and Drug Administration for prostate cancer.[1][2] In April 2017, seviteronel received fast-track designation for breast cancer as well.[1]
Pharmacology
Pharmacodynamics
Seviteronel is a
abiraterone (the active metabolite of abiraterone acetate), which has IC50 values for inhibition of 17,20-lyase and 17α-hydroxylase of 15 nM and 2.5 nM, respectively.[7] In addition, in in vitro models, seviteronel appears to possess greater efficacy as an antiandrogen relative to abiraterone.[6] Similarly to abiraterone acetate, seviteronel has also been found to act to some extent as an antagonist of the androgen receptor.[6]
Society and culture
Generic names
Seviteronel is the
INN.[10]
See also
References
- ^ a b c d e "Seviteronel - Innocrin Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
- ^ "FDA grants fast-track status for Innocrin's seviteronel to treat metastatic CRPC". PharmaceuticalTechnology. 6 January 2016.
- PMID 23880851.
- PMID 24759590.
- PMID 24775307.
- ^ PMID 25351916.
- ^ ISBN 978-0-12-397228-6.
- ISBN 978-1-936287-59-8.
- PMID 27154414.
VT464 is another recently developed compound proposed to act as a selective lyase inhibitor, and more complete data is available in the public domain to support this claim. A review of preliminary data released suggest the IC50 for Human CYP17 lyase activity is ten times lower than for hydroxylase 15 and in nonhuman primates VT464 was able to suppress circulating testosterone as effectively as abiraterone, but with minimally depressed cortisol (remaining at 82% control compared to only 9% with aberaterone), and without associated increases in pregnenolone, progesterone and mineralocorticoids otherwise observed with abiraterone. Like Galaterone, VT464 is also in use in clinical trials without co-administration of prednisone. Together with the clear lack of suppression of circulating cortisol in nonhuman primates, these data argue that VT464 may indeed be a selective 17,20 lyase inhibitor.
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 30 (3). World Health Organization: 533. 2016. Archived from the original (PDF) on 2022-02-16.
Further reading
- Gomez L, Kovac JR, Lamb DJ (March 2015). "CYP17A1 inhibitors in castration-resistant prostate cancer". Steroids. 95: 80–87. PMID 25560485.
- Bambury RM, Rathkopf DE (August 2016). "Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide". Urologic Oncology. 34 (8): 348–355. PMID 26162486.